查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1679250

2030 年重组人胰岛素市场预测：按产品、品牌、通路和地区进行的全球分析

Recombinant Human Insulin Market Forecasts to 2030 - Global Analysis By Product, Brand, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球重组人胰岛素市场预计在 2024 年达到 209.7 亿美元，到 2030 年将达到 289.1 亿美元，预测期内的复合年增长率为 5.5%。

重组人类胰岛素是利用重组 DNA 技术製成的荷尔蒙合成形式，主要在酵母（酿酒酵母）或大肠桿菌等基因改造细菌中产生。在引入之前，动物源胰岛素被广泛使用，但它已被开发为更有效、更安全的替代品。此外，重组人胰岛素透过模拟人体自然产生的荷尔蒙来帮助控製糖尿病患者的血糖值。为了生产它，人类胰岛素基因被插入微生物细胞，然后使用受控的发酵过程合成蛋白质。

根据国际糖尿病联盟（IDF）的数据，到 2030 年，患有糖尿病的成年人数量预计将达到 6.43 亿。

糖尿病盛行率不断上升

全球糖尿病盛行率的上升，特别是第 1 型糖尿病和胰岛素依赖型 2 型糖尿病，大大推动了重组人类胰岛素市场的发展。根据国际糖尿病联盟（IDF）的数据，预计到2030年糖尿病患者数量将增加至6.43亿，到2045年将增加至7.83亿，因此对胰岛素治疗的需求将急剧增加。此外，由于久坐不动、饮食不良和生活方式的改变，糖尿病变得越来越普遍，增加了对胰岛素维持血糖控制的需求。

昂贵的胰岛素治疗

重组人类胰岛素的高价格是其市场化的最大障碍之一，限制了其可及性，尤其是在中低收入国家（LMIC）。即使有生物相似药胰岛素，由于昂贵的製造方法、大型製药公司的垄断定价策略以及专利保护，定价仍然是一个问题。世界卫生组织（WHO）声称，开发中国家的许多人无法负担胰岛素，导致疾病控制不佳和糖尿病相关併发症增加。此外，高昂的自付费用限制了胰岛素疗法的广泛应用，这给医疗保健系统带来了压力。

胰岛素输送系统技术的发展

胰岛素输送技术的进步提供了巨大的成长潜力。人工胰臟系统、胰岛素帮浦、智慧胰岛素笔和持续血糖监测 (CGM) 设备的发展都在提高准确性、便利性和患者依从性。透过提供自动剂量调整和即时血糖监测，穿戴式自动化胰岛素输送系统可降低低血糖和血糖波动的风险。此外，重组人类胰岛素在先进治疗方案中的应用可能会受到数位医疗和智慧医疗设备进步的推动。

严格的监管核准程序

对重组人胰岛素製剂的严格法律规范导致了冗长的核准流程和高昂的遵循成本。胰岛素製剂必须符合欧洲药品管理局（EMA）、美国食品药物管理局（FDA）和中国国家药品监督（NMPA）等监管机构所製定的严格的安全性、有效性和品质标准。此外，核准生物相似药胰岛素所需的漫长的比较研究、临床试验和上市后监测可能会延迟我们的产品推出并增加我们的营运成本。

COVID-19 的影响：

由于全球供应链中断、临床试验延迟以及医疗系统压力，COVID-19 疫情对重组人类胰岛素市场产生了重大影响。由于封锁和运输限制导致的胰岛素生产和分配延迟以及原材料短缺影响了市场供应，特别是在中低收入国家。经济拮据和失业也使患者难以获得胰岛素治疗，并降低了治疗顺从性。但疫情也加速了家庭糖尿病管理计画和远端医疗的采用，并增加了对患者使用的胰岛素输送设备（如胰岛素帮浦和胰岛素笔）的需求。

预测期内，预混合料人胰岛素市场预计将成为最大的市场

预计预测期内预混合料人胰岛素部分将占据市场占有率。透过结合精确比例的短效和中效胰岛素，预混合料人胰岛素可减少每日註射次数、简化给药时间表，进而提高患者的遵从性。这种配方对于需要控制基础血糖和餐前血糖的第 2 型糖尿病患者特别有用。此外，由于全球糖尿病盛行率不断上升，以及对易于使用的胰岛素治疗的需求不断增加，预混合料人胰岛素的使用量不断上升，从而确保了其市场领先地位。

预计预测期内，Humulin R 部分将以最高的复合年增长率成长。

预计预测期内 Humulin R 领域将呈现最高成长率。 优泌林 R 是一种短效胰岛素，常用于控制餐后血糖值。它的快速作用使其成为强化胰岛素治疗的重要组成部分。推动市场成长的关键因素包括第 2 型糖尿病盛行率上升、自我管理胰岛素输送系统的使用增加以及对生物相似药胰岛素製剂的需求不断增长。此外，胰岛素帮浦技术的持续发展以及优泌林 R 融入混合闭合迴路系统也支持了其强劲的成长轨迹。

比最大的地区

在预测期内，由于糖尿病盛行率高、医疗保健系统完善以及尖端胰岛素输送技术的广泛使用，预计北美将占据最大的市场占有率。该地区受益于不断增长的糖尿病患者数量（尤其是美国）、完善的报销政策以及对生物相似药胰岛素不断增长的需求。顶级胰岛素製造商的存在、持续的研发投入以及政府改善糖尿病治疗的计划进一步增强了北美的优势。此外，由于消费者对智慧胰岛素笔和帮浦的偏好增加，该地区的市场正在稳步增长。

复合年增长率最高的地区：

预计预测期内亚太地区将呈现最高的复合年增长率。这是由于中国、印度和日本等国家不断扩大胰岛素治疗的覆盖率、医疗成本的上升以及糖尿病患者数量的快速增加。市场扩张的驱动因素包括生物相似药胰岛素的使用增加、政府改善糖尿病护理基础设施的计划以及庞大的未开发患者群体。此外，都市化加快、生活方式改变导致糖尿病盛行率上升、人们对自我管理胰岛素输送设备的认识不断提高，都是支持该地区市场强劲成长轨迹的因素。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业的 SWOT 分析（最多 3 家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争性基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二手研究资料资讯来源
    • 先决条件

第三章 市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 产品分析
  • 新兴市场
  • COVID-19 的影响

第 4 章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球重组人胰岛素市场（依产品划分）

  • 短效人胰岛素
  • 中效人胰岛素
  • 混合人类胰岛素

6. 全球重组人类胰岛素市场（按品牌）

  • 优泌林R
  • 诺和灵
  • 优泌林
  • 诺和灵 N
  • 其他品牌

7. 全球重组人胰岛素市场（按分销管道）

  • 医院
  • 零售药局
  • 网路药局
  • 其他分销管道

8. 全球重组人类胰岛素市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第九章 主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司概况

  • AstraZeneca Ltd
  • Eli Lilly and Company
  • Sanofi SA
  • Gan & Lee Pharmaceuticals, Ltd
  • Dongbao Enterprise Group Co Ltd.
  • Merck KGaA
  • Biocon Limited
  • Zhuhai United Laboratories Co., Ltd
  • Duopharma Marketing Sdn Bhd
  • Julphar Gulf Pharmaceutical Industries
  • Novo Nordisk A/S
  • Sigma-Aldrich Inc
  • Bioton SA
  • Pfizer Inc
  • Wanbang Biopharmaceuticals Co., Ltd
Product Code: SMRC28833

According to Stratistics MRC, the Global Recombinant Human Insulin Market is accounted for $20.97 billion in 2024 and is expected to reach $28.91 billion by 2030 growing at a CAGR of 5.5% during the forecast period. Recombinant human insulin is a synthetic form of the hormone that is made using recombinant DNA technology, mostly in yeast (Saccharomyces cerevisiae) or genetically modified bacteria like Escherichia coli. It was created as a more effective and safe substitute for the widely used insulin derived from animal sources prior to its introduction. Moreover, recombinant human insulin helps diabetics control their blood glucose levels by simulating the body's natural production of the hormone. In order to produce it, the human insulin gene is inserted into microbial cells, which subsequently use regulated fermentation processes to synthesize the protein.

According to the International Diabetes Federation (IDF), the number of adults with diabetes is projected to reach 643 million by 2030.

Market Dynamics:

Driver:

Growing prevalence of diabetes

The market for recombinant human insulin is largely driven by the rising prevalence of diabetes worldwide, especially type 1 and insulin-dependent type-2 diabetes. The demand for insulin-based treatments is predicted to rise dramatically as the number of people with diabetes rises to 643 million by 2030 and 783 million by 2045, according to the International Diabetes Federation (IDF). Additionally, diabetes is also becoming more common due to sedentary lifestyles, poor diets, and altered lifestyles, which increases the need for insulin to maintain glycemic control.

Restraint:

Expensive insulin therapy

The high cost of recombinant human insulin is one of the biggest barriers to its market, limiting accessibility, particularly in low- and middle-income countries (LMICs). Because of costly production methods, monopolistic pricing tactics by large pharmaceutical companies, and patent protections, prices are still an issue even with the availability of bio-similar insulin. The World Health Organization (WHO) claims that a large number of people in developing nations cannot afford insulin, which results in inadequate disease management and a rise in complications associated with diabetes. Furthermore, limiting the widespread use of insulin therapy is the high out-of-pocket costs, which can strain healthcare systems.

Opportunity:

Developments in insulin delivery system technology

Technological advancements in insulin delivery present substantial growth prospects. Precision, convenience, and patient adherence are all improved by the development of artificial pancreas systems, insulin pumps, smart insulin pens, and continuous glucose monitoring (CGM) devices. By offering automated dosing adjustments and real-time glucose monitoring, wearable and automated insulin delivery systems lower the risk of hypoglycemia and blood sugar swings. Moreover, the use of recombinant human insulin in sophisticated therapeutic solutions will be fueled by advancements in digital healthcare and smart medical devices.

Threat:

Strict approval procedure for regulation

Strict regulatory oversight of recombinant human insulin products results in lengthy approval processes and expensive compliance expenses. Insulin production must meet strict safety, efficacy, and quality standards set by regulatory bodies like the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and China's National Medical Products Administration (NMPA). Additionally, the lengthy comparability studies, clinical trials, and post-market surveillance required for bio-similar insulin approvals can cause delays in product launches and raise operating expenses.

Covid-19 Impact:

Due to the disruption of global supply chains, the delay of clinical trials, and the strain on healthcare systems, the COVID-19 pandemic had a major effect on the market for recombinant human insulin. Insulin production and distribution were delayed, and raw material shortages resulted from lockdowns and transportation restrictions, which impacted market availability, especially in low- and middle-income nations. Financial limitations and job losses also made it harder for patients to afford insulin therapy, which decreased adherence. However, the pandemic also hastened the adoption of home-based diabetes management programs and telemedicine, which has increased demand for insulin delivery devices that can be used by the patients themselves, such as insulin pumps and pens.

The Premixed Human Insulin segment is expected to be the largest during the forecast period

The Premixed Human Insulin segment is expected to account for the largest market share during the forecast period. Premixed human insulin improves patient compliance by reducing the number of daily injections and simplifying dosing schedules by combining precise ratios of short-acting and intermediate-acting insulin. For people with type 2 diabetes who need both basal and prandial glycemic control, this formulation is especially helpful. Moreover, the use of premixed human insulin has increased due to the rising incidence of diabetes worldwide and the growing need for insulin treatments that are easy to use, thereby securing its market leadership.

The Humulin R segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Humulin R segment is predicted to witness the highest growth rate. Humulin R is short-acting insulin that is frequently used to control postprandial blood glucose levels. Because of its quick onset of action, it is an essential part of intensive insulin therapy. Key drivers of its market expansion include the rising incidence of type 2 diabetes, the growing use of self-administration insulin delivery systems, and the rising need for bio-similar insulin formulations. Additionally, its robust growth trajectory has also been aided by continuous developments in insulin pump technology and the incorporation of Humulin R into hybrid closed-loop systems.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by the high rate of diabetes, the sophisticated medical system, and the widespread use of cutting-edge insulin delivery technologies. The region benefits from a growing number of diabetics, especially in the US, well-established reimbursement policies, and rising demand for biosimilar insulin. North America's dominance is further reinforced by the existence of top insulin producers, ongoing R&D expenditures, and government programs to improve diabetes care. Furthermore, the region's market is growing steadily due in part to consumers' growing preference for smart insulin pens and pumps.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by nations like China, India, and Japan's expanding access to insulin therapies, rising healthcare costs, and the fast-growing number of people with diabetes. Growing use of bio-similar insulin, government programs to upgrade the infrastructure for diabetes care and the existence of a sizable untapped patient base are all driving market expansion. Moreover, growing urbanization, lifestyle changes that contribute to a higher prevalence of diabetes and growing awareness of self-administration insulin delivery devices all support the market's robust growth trajectory in this region.

Key players in the market

Some of the key players in Recombinant Human Insulin market include AstraZeneca Ltd, Eli Lilly and Company, Sanofi S.A, Gan & Lee Pharmaceuticals, Ltd, Dongbao Enterprise Group Co Ltd., Merck KGaA, Biocon Limited, Zhuhai United Laboratories Co., Ltd, Duopharma Marketing Sdn Bhd, Julphar Gulf Pharmaceutical Industries, Novo Nordisk A/S, Sigma-Aldrich Inc, Bioton S.A, Pfizer Inc and Wanbang Biopharmaceuticals Co., Ltd.

Key Developments:

In September 2024, Biocon Ltd said it has signed a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company to commercialise its 'GLP-1' products for treating diabetes and chronic weight management in select countries of the Middle East. Under the agreement, the company will develop and manufacture the products and Tabuk Pharmaceuticals -- a fully-owned subsidiary of Astra Industrial Group, a leading pharmaceutical company in the Middle East and North Africa (MENA) region.

In July 2024, Merck has signed an agreement to sell its global Surface Solutions business unit to Global New Material International Holdings Ltd. for € 665 million in cash. Merck intends to use the net proceeds from the divestment to further strengthen its strategic core businesses.

In March 2024, AstraZeneca Pharma India and Mankind Pharma has entered into an agreement for exclusive distribution of AstraZeneca's budesonide and formoterol fumarate dihydrate brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and long-acting beta-agonist and will continue to be the marketing authorisation holder (MAH) and import license.

Products Covered:

  • Short-Acting Human Insulin
  • Intermediate-Acting Human Insulin
  • Premixed Human Insulin

Brands Covered:

  • Humulin R
  • Novolin R
  • Humulin N
  • Novolin N
  • Other Brands

Distribution Channels Covered:

  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Recombinant Human Insulin Market, By Product

  • 5.1 Introduction
  • 5.2 Short-Acting Human Insulin
  • 5.3 Intermediate-Acting Human Insulin
  • 5.4 Premixed Human Insulin

6 Global Recombinant Human Insulin Market, By Brand

  • 6.1 Introduction
  • 6.2 Humulin R
  • 6.3 Novolin R
  • 6.4 Humulin N
  • 6.5 Novolin N
  • 6.6 Other Brands

7 Global Recombinant Human Insulin Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies
  • 7.5 Other Distribution Channels

8 Global Recombinant Human Insulin Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 AstraZeneca Ltd
  • 10.2 Eli Lilly and Company
  • 10.3 Sanofi S.A
  • 10.4 Gan & Lee Pharmaceuticals, Ltd
  • 10.5 Dongbao Enterprise Group Co Ltd.
  • 10.6 Merck KGaA
  • 10.7 Biocon Limited
  • 10.8 Zhuhai United Laboratories Co., Ltd
  • 10.9 Duopharma Marketing Sdn Bhd
  • 10.10 Julphar Gulf Pharmaceutical Industries
  • 10.11 Novo Nordisk A/S
  • 10.12 Sigma-Aldrich Inc
  • 10.13 Bioton S.A
  • 10.14 Pfizer Inc
  • 10.15 Wanbang Biopharmaceuticals Co., Ltd

List of Tables

  • Table 1 Global Recombinant Human Insulin Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Recombinant Human Insulin Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Recombinant Human Insulin Market Outlook, By Short-Acting Human Insulin (2022-2030) ($MN)
  • Table 4 Global Recombinant Human Insulin Market Outlook, By Intermediate-Acting Human Insulin (2022-2030) ($MN)
  • Table 5 Global Recombinant Human Insulin Market Outlook, By Premixed Human Insulin (2022-2030) ($MN)
  • Table 6 Global Recombinant Human Insulin Market Outlook, By Brand (2022-2030) ($MN)
  • Table 7 Global Recombinant Human Insulin Market Outlook, By Humulin R (2022-2030) ($MN)
  • Table 8 Global Recombinant Human Insulin Market Outlook, By Novolin R (2022-2030) ($MN)
  • Table 9 Global Recombinant Human Insulin Market Outlook, By Humulin N (2022-2030) ($MN)
  • Table 10 Global Recombinant Human Insulin Market Outlook, By Novolin N (2022-2030) ($MN)
  • Table 11 Global Recombinant Human Insulin Market Outlook, By Other Brands (2022-2030) ($MN)
  • Table 12 Global Recombinant Human Insulin Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 13 Global Recombinant Human Insulin Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 14 Global Recombinant Human Insulin Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 15 Global Recombinant Human Insulin Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 16 Global Recombinant Human Insulin Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
  • Table 17 North America Recombinant Human Insulin Market Outlook, By Country (2022-2030) ($MN)
  • Table 18 North America Recombinant Human Insulin Market Outlook, By Product (2022-2030) ($MN)
  • Table 19 North America Recombinant Human Insulin Market Outlook, By Short-Acting Human Insulin (2022-2030) ($MN)
  • Table 20 North America Recombinant Human Insulin Market Outlook, By Intermediate-Acting Human Insulin (2022-2030) ($MN)
  • Table 21 North America Recombinant Human Insulin Market Outlook, By Premixed Human Insulin (2022-2030) ($MN)
  • Table 22 North America Recombinant Human Insulin Market Outlook, By Brand (2022-2030) ($MN)
  • Table 23 North America Recombinant Human Insulin Market Outlook, By Humulin R (2022-2030) ($MN)
  • Table 24 North America Recombinant Human Insulin Market Outlook, By Novolin R (2022-2030) ($MN)
  • Table 25 North America Recombinant Human Insulin Market Outlook, By Humulin N (2022-2030) ($MN)
  • Table 26 North America Recombinant Human Insulin Market Outlook, By Novolin N (2022-2030) ($MN)
  • Table 27 North America Recombinant Human Insulin Market Outlook, By Other Brands (2022-2030) ($MN)
  • Table 28 North America Recombinant Human Insulin Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 29 North America Recombinant Human Insulin Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 30 North America Recombinant Human Insulin Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 31 North America Recombinant Human Insulin Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 32 North America Recombinant Human Insulin Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
  • Table 33 Europe Recombinant Human Insulin Market Outlook, By Country (2022-2030) ($MN)
  • Table 34 Europe Recombinant Human Insulin Market Outlook, By Product (2022-2030) ($MN)
  • Table 35 Europe Recombinant Human Insulin Market Outlook, By Short-Acting Human Insulin (2022-2030) ($MN)
  • Table 36 Europe Recombinant Human Insulin Market Outlook, By Intermediate-Acting Human Insulin (2022-2030) ($MN)
  • Table 37 Europe Recombinant Human Insulin Market Outlook, By Premixed Human Insulin (2022-2030) ($MN)
  • Table 38 Europe Recombinant Human Insulin Market Outlook, By Brand (2022-2030) ($MN)
  • Table 39 Europe Recombinant Human Insulin Market Outlook, By Humulin R (2022-2030) ($MN)
  • Table 40 Europe Recombinant Human Insulin Market Outlook, By Novolin R (2022-2030) ($MN)
  • Table 41 Europe Recombinant Human Insulin Market Outlook, By Humulin N (2022-2030) ($MN)
  • Table 42 Europe Recombinant Human Insulin Market Outlook, By Novolin N (2022-2030) ($MN)
  • Table 43 Europe Recombinant Human Insulin Market Outlook, By Other Brands (2022-2030) ($MN)
  • Table 44 Europe Recombinant Human Insulin Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 45 Europe Recombinant Human Insulin Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 46 Europe Recombinant Human Insulin Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 47 Europe Recombinant Human Insulin Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 48 Europe Recombinant Human Insulin Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
  • Table 49 Asia Pacific Recombinant Human Insulin Market Outlook, By Country (2022-2030) ($MN)
  • Table 50 Asia Pacific Recombinant Human Insulin Market Outlook, By Product (2022-2030) ($MN)
  • Table 51 Asia Pacific Recombinant Human Insulin Market Outlook, By Short-Acting Human Insulin (2022-2030) ($MN)
  • Table 52 Asia Pacific Recombinant Human Insulin Market Outlook, By Intermediate-Acting Human Insulin (2022-2030) ($MN)
  • Table 53 Asia Pacific Recombinant Human Insulin Market Outlook, By Premixed Human Insulin (2022-2030) ($MN)
  • Table 54 Asia Pacific Recombinant Human Insulin Market Outlook, By Brand (2022-2030) ($MN)
  • Table 55 Asia Pacific Recombinant Human Insulin Market Outlook, By Humulin R (2022-2030) ($MN)
  • Table 56 Asia Pacific Recombinant Human Insulin Market Outlook, By Novolin R (2022-2030) ($MN)
  • Table 57 Asia Pacific Recombinant Human Insulin Market Outlook, By Humulin N (2022-2030) ($MN)
  • Table 58 Asia Pacific Recombinant Human Insulin Market Outlook, By Novolin N (2022-2030) ($MN)
  • Table 59 Asia Pacific Recombinant Human Insulin Market Outlook, By Other Brands (2022-2030) ($MN)
  • Table 60 Asia Pacific Recombinant Human Insulin Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 61 Asia Pacific Recombinant Human Insulin Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 62 Asia Pacific Recombinant Human Insulin Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 63 Asia Pacific Recombinant Human Insulin Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 64 Asia Pacific Recombinant Human Insulin Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
  • Table 65 South America Recombinant Human Insulin Market Outlook, By Country (2022-2030) ($MN)
  • Table 66 South America Recombinant Human Insulin Market Outlook, By Product (2022-2030) ($MN)
  • Table 67 South America Recombinant Human Insulin Market Outlook, By Short-Acting Human Insulin (2022-2030) ($MN)
  • Table 68 South America Recombinant Human Insulin Market Outlook, By Intermediate-Acting Human Insulin (2022-2030) ($MN)
  • Table 69 South America Recombinant Human Insulin Market Outlook, By Premixed Human Insulin (2022-2030) ($MN)
  • Table 70 South America Recombinant Human Insulin Market Outlook, By Brand (2022-2030) ($MN)
  • Table 71 South America Recombinant Human Insulin Market Outlook, By Humulin R (2022-2030) ($MN)
  • Table 72 South America Recombinant Human Insulin Market Outlook, By Novolin R (2022-2030) ($MN)
  • Table 73 South America Recombinant Human Insulin Market Outlook, By Humulin N (2022-2030) ($MN)
  • Table 74 South America Recombinant Human Insulin Market Outlook, By Novolin N (2022-2030) ($MN)
  • Table 75 South America Recombinant Human Insulin Market Outlook, By Other Brands (2022-2030) ($MN)
  • Table 76 South America Recombinant Human Insulin Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 77 South America Recombinant Human Insulin Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 78 South America Recombinant Human Insulin Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 79 South America Recombinant Human Insulin Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 80 South America Recombinant Human Insulin Market Outlook, By Other Distribution Channels (2022-2030) ($MN)
  • Table 81 Middle East & Africa Recombinant Human Insulin Market Outlook, By Country (2022-2030) ($MN)
  • Table 82 Middle East & Africa Recombinant Human Insulin Market Outlook, By Product (2022-2030) ($MN)
  • Table 83 Middle East & Africa Recombinant Human Insulin Market Outlook, By Short-Acting Human Insulin (2022-2030) ($MN)
  • Table 84 Middle East & Africa Recombinant Human Insulin Market Outlook, By Intermediate-Acting Human Insulin (2022-2030) ($MN)
  • Table 85 Middle East & Africa Recombinant Human Insulin Market Outlook, By Premixed Human Insulin (2022-2030) ($MN)
  • Table 86 Middle East & Africa Recombinant Human Insulin Market Outlook, By Brand (2022-2030) ($MN)
  • Table 87 Middle East & Africa Recombinant Human Insulin Market Outlook, By Humulin R (2022-2030) ($MN)
  • Table 88 Middle East & Africa Recombinant Human Insulin Market Outlook, By Novolin R (2022-2030) ($MN)
  • Table 89 Middle East & Africa Recombinant Human Insulin Market Outlook, By Humulin N (2022-2030) ($MN)
  • Table 90 Middle East & Africa Recombinant Human Insulin Market Outlook, By Novolin N (2022-2030) ($MN)
  • Table 91 Middle East & Africa Recombinant Human Insulin Market Outlook, By Other Brands (2022-2030) ($MN)
  • Table 92 Middle East & Africa Recombinant Human Insulin Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 93 Middle East & Africa Recombinant Human Insulin Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 94 Middle East & Africa Recombinant Human Insulin Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 95 Middle East & Africa Recombinant Human Insulin Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 96 Middle East & Africa Recombinant Human Insulin Market Outlook, By Other Distribution Channels (2022-2030) ($MN)